Hepcidin: a new tool in the management of anaemia in patients with chronic kidney disease?
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
The introduction of erythropoiesis-stimulating agents (ESA), such as recombinant human erythropoietin (EPO) has allowed effective treatment of anaemia in patients with chronic kidney disease (CKD). However, the optimal target level of haemoglobin is debated and many patients are resistant to ESA. Hepcidin is a recently discovered low-molecular-weight protein that plays an important role in iron metabolism. Hepcidin may be relevant in CKD and explain the often-observed disbalance in iron metabolism and the resistance to ESA. As such hepcidin could become an important tool to predict ESA responsiveness and to guide treatment with ESA and intravenous iron. In addition, hepcidin has the potential to become a target of treatment. In this review we summarize the pathophysiology of hepcidin and discuss its potential relevance for patients with CKD. Human hepcidin is produced by hepatocytes as an 84-amino-acid (aa) pre-prohepcidin [ 1 ]. Subsequent posttranslational processing results in the biologically active 25 aa form (hepcidin-25) that is secreted in the plasma. Additional amino-terminal degradation results in the production of two smaller isoforms (hepcidin-20 and -22), the biological significance of which is unknown [ 2 ]. Hepcidin is the key regulator of systemic iron homeostasis. Hepcidin leads to internalization and degradation of the iron exporter ferroportin, which is present on the cell surface of macrophages and enterocytes [ 3,4 ]. Thus, hepcidin inhibits the release of iron by macrophages and attenuates the iron uptake in the gut. In addition to these effects on body iron distribution, hepcidin might also directly inhibit erythroid-progenitor proliferation and survival [ 5 ]. Increased iron stores and inflammation induce hepcidin production, whereas hypoxia, anaemia, iron deficiency, increased erythropoiesis and ESA attenuate hepcidin synthesis [ 6–10 , Figure 1]. Thus, inflammation decreases the availability of iron, whereas hypoxia or anaemia increases iron release and absorption. Recent studies demonstrated that the hypoxia-inducible factor (HIF)-1 alpha contributes to the (down-) regulation of hepcidin, which was suggested to be a direct transcriptional mechanism [ 11 ] or mediated by muscle-derived soluble haemojuvelin, which may be increased by the HIF-dependent induction of furin activity [ 12 ]. However, the molecular mechanisms of the hypoxic or anaemic regulation of hepcidin are far from being understood. Several studies demonstrated that the induction of erythropoiesis and not hypoxia or anaemia itself down-regulates hepcidin [ 8 , 11–13 ]. ESA increase the erythropoietic activity, and thus iron must be rapidly mobilized from the stores to satisfy the needs of the bone marrow. The reported decrease in circulating hepcidin levels by ESA treatment [ 6 , 8 , 13 ] may explain the fast iron release. The relationship between hepcidin production and erythropoiesis suggests the presence of a regulator between the erythron and the liver, and several candidates for this role have been proposed, for example the soluble transferrin receptor (sTfR) [ 14,15 ] and the growth differentiation factor (GDF)-15 [ 16 ]. Until recently few investigative tools were available to measure hepcidin in human biological samples. Many studies measured the precursor prohepcidin using a commercially available ELISA. The relevance of these data is controversial because prohepcidin levels do not correlate with urinary and serum hepcidin, nor do they respond to relevant physiological stimuli [ 14 , 17–19 ]. Moreover, in vitro studies do not show a fixed relation between hepatocyte prohepcidin and hepcidin release [ 20 ]. Nevertheless, significant changes in prohepcidin concentration have been reported in ferroportin disease [ 21 ] and in patients with CKD [ 22–24 ]. Ganz and Nemeth et al . have developed a dot blot assay using non-commercially available antibodies for the semi-quantitative measurement of hepcidin in urine [ 25 ]. More recently, new assays have been developed exploiting novel technologies such as surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) and liquid chromatography tandem mass spectrometry (LC/MS-MS) [ 26–30 ]. With the use of internal standards these mass spectrometry techniques enable reliable quantitative hepcidin analysis in urine and serum (our unpublished data). To date, most studies have reported urinary hepcidin concentration. Although these urinary data nicely fit in the concept of hepcidin as the iron regulatory peptide [ 9,10 ] and concentrations of urine and serum highly correlate [ 27 ], we caution against the use of urine hepcidin measurements since urinary secretion of hepcidin will depend on glomerular filtration and tubular reabsorption. Furthermore hepcidin mRNA has been detected in the kidney, which suggests the potential for local production and release into the urine [ 31 ]. Thus, serum and urine levels can technically reliably be measure
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hepcidin Regulates Cellular Iron Efflux by Binding to Ferroportin and Inducing Its Internalization
Nemeth, E., Tuttle, M. S., Powelson, J., Vaughn, M. B., Donovan, A., Ward, D. M., Ganz, T., & Kaplan, J. (2004) · Science · doi:10.1126/science.1104742 · Cited by 4,803 · cited 1×
“Hepcidin leads to internalization and degradation of the iron exporter ferroportin, which is present on the cell surface of macrophages and enterocytes [3,4].”
BackgroundCorrection of anemia with epoetin alfa in chronic kidney disease
Singh, A. K., Szczech, L., Tang, K. L., Barnhart, H., Sapp, S., Wolfson, M., & Reddan, D. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa065485 · Cited by 2,762
Hepcidin, a urinary antimicrobial peptide synthesized in the liver
Park, C. H., Valore, E. V., Waring, A. J., & Ganz, T. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008922200 · Cited by 2,168 · cited 1×
“Additional amino-terminal degradation results in the production of two smaller isoforms (hepcidin-20 and -22), the biological significance of which is unknown [2].”
BackgroundBesarab, A., Bolton, W. K., Browne, J. K., Egrie, J. C., Nissenson, A. R., Okamoto, D. M., Schwab, S. J., & Goodkin, D. A. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808273390903 · Cited by 1,930
Pigeon, C., Ilyin, G., Courselaud, B., Leroyer, P., Turlin, B., Brissot, P., & Loréal, O. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008923200 · Cited by 1,697 · cited 1×
“Human hepcidin is produced by hepatocytes as an 84-amino-acid (aa) pre-prohepcidin [1].”
BackgroundHepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein
Nemeth, E., Valore, E. V., Territo, M., Schiller, G., Lichtenstein, A., & Ganz, T. (2003) · Blood · doi:10.1182/blood-2002-10-3235 · Cited by 1,417 · cited 1×
“have developed a dot blot assay using non-commercially available antibodies for the semi-quantitative measurement of hepcidin in urine [25].”
MethodHigh levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin
Tanno, T., Bhanu, N. V., Oneal, P. A., Goh, S.-H., Staker, P., Lee, Y. T., Moroney, J. W., Reed, C. H., Luban, N. L., Wang, R.-H., et al. (2007) · Nature Medicine · doi:10.1038/nm1629 · Cited by 854 · cited 1×
“The relationship between hepcidin production and erythropoiesis suggests the presence of a regulator between the erythron and the liver, and several candidates for this role have been proposed, for example the soluble transferrin receptor (sTfR) [14,15] and the growth differentiation factor (GDF)-15 [16].”
BackgroundRegulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs)
Peyssonnaux, C., Zinkernagel, A. S., Schuepbach, R. A., Rankin, E., Vaulont, S., Haase, V. H., Nizet, V., & Johnson, R. S. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31370 · Cited by 639 · cited 1×
“Recent studies demonstrated that the hypoxia-inducible factor (HIF)-1 alpha contributes to the (down-) regulation of hepcidin, which was suggested to be a direct transcriptional mechanism [11] or mediated by muscle-derived soluble haemojuvelin, which may be increased by the HIF-dependent induction of furin activity [1…”
BackgroundTime-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS
Kemna, E., Pickkers, P., Nemeth, E., van der Hoeven, H., & Swinkels, D. (2005) · Blood · doi:10.1182/blood-2005-03-1159 · Cited by 498
Self-citationSuppression of hepcidin during anemia requires erythropoietic activity
Pak, M., Lopez, M. A., Gabayan, V., Ganz, T., & Rivera, S. (2006) · Blood · doi:10.1182/blood-2006-06-028787 · Cited by 472 · cited 1×
“The reported decrease in circulating hepcidin levels by ESA treatment [6,8,13] may explain the fast iron release.”
Background
Cited by
Kell, D. B. (2009) · BMC Medical Genomics · doi:10.1186/1755-8794-2-2 · Cited by 554
Macdougall, I. C., Bircher, A. J., Eckardt, K.-U., Obrador, G. T., Pollock, C. A., Stenvinkel, P., Swinkels, D. W., Wanner, C., Weiss, G., Chertow, G. M., et al. (2016) · Kidney International · doi:10.1016/j.kint.2015.10.002 · Cited by 482
Self-citationMultiple loci influence erythrocyte phenotypes in the CHARGE Consortium
Ganesh, S. K., Zakai, N. A., van Rooij, F. J. A., Soranzo, N., Smith, A. V., Nalls, M. A., Chen, M.-H., Kottgen, A., Glazer, N. L., Dehghan, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.466 · Cited by 358
Hepcidin—A Potential Novel Biomarker for Iron Status in Chronic Kidney Disease
Zaritsky, J., Young, B., Wang, H.-J., Westerman, M., Olbina, G., Nemeth, E., Ganz, T., Rivera, S., Nissenson, A. R., & Salusky, I. B. (2009) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.05931108 · Cited by 350
Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease
Ashby, D. R., Gale, D. P., Busbridge, M., Murphy, K. G., Duncan, N. D., Cairns, T. D., Taube, D. H., Bloom, S. R., Tam, F. W. K., Chapman, R. S., et al. (2009) · Kidney International · doi:10.1038/ki.2009.21 · Cited by 311
Metadata
- Authors
- Swinkels, D. W., & Wetzels, J. F. M.
- Venue
- Nephrology Dialysis Transplantation
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-04-02
- Volume
- 23
- Issue
- 8
- Pages
- 2450-2453
- ISSN
- 0931-0509 (ISSN-L)
- 1460-2385
- OpenAlex
- W2108325722
- Cited by
- 80
- References
- 14
- FWCI
- 5.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Hepcidin: a new tool in the management of anaemia in patients with chronic kidney disease? https://app.cochat.ai/papers/10.1093/ndt/gfn267
- The paper
- Swinkels, D. W., & Wetzels, J. F. M. (2008). Hepcidin: a new tool in the management of anaemia in patients with chronic kidney disease? Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfn267
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.